• Kits Combine the Power of HiFi Sequencing and Nanobind Technology to Optimize Sample Preparation Workflows for High Volume Customers

MENLO Park, Calif., April 5, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the availability of its new high-throughput (HT) Nanobind DNA Extraction kits, another key product from the highly valuable Circulomics acquisition. These kits are designed to enable researchers to extract high-quality DNA from a wide range of samples in a high-throughput setting, with a simple and rapid protocol that is compatible with platforms from leading automation providers.

Using scripts now available through some of PacBio's Compatible partners, the HT Nanobind DNA Extraction kits, along with PacBio's long-read sequencing technology, researchers will have the tools to complete accurate genome assemblies, identify structural variants, and explore complex biological systems in extraordinary detail in high-throughput labs. This represents another step towards PacBio's commitment to further address the needs of high-throughput customers, who began taking delivery of their first Revio sequencing systems during the first quarter of 2023.

"The availability of the HT Nanobind DNA Extraction kits represents a major advancement in DNA extraction technology, with significant benefits for researchers in genomics, microbiology, and many other fields," said Jeff Eidel, Chief Commercial Officer at PacBio. "By enabling fast, reliable, and scalable DNA extraction, we believe these kits will accelerate research across a wide range of applications. The HT Nanobind DNA Extraction kits offer a solution to the potential bottleneck of sample preparation. As we've shown with the Sample Preparation Kit 3.0 that was launched in July 2022, we will continue to focus on scaling and automating every step of the long-read sequencing workflow."

The HT Nanobind DNA Extraction kits are based on proprietary Nanobind disks, which are composed of a porous, silica-based material that efficiently binds and releases high molecular weight DNA. The disks can be used for the extraction of DNA from diverse sample types, including blood, cell, and tissue samples. With this technology, researchers can extract high-quality DNA in less than two hours, with minimal sample input and without the use of harmful chemicals or mechanical homogenization.

The new HT Nanobind DNA Extraction kits are available now from PacBio and its authorized distributors worldwide. For more information, please visit PacBio's Online Store.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB® short read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including in connection with the high-throughput (HT) Nanobind DNA Extraction kits; the ability of researchers to complete accurate genome assemblies, identify structural variants, accelerate research, explore complex biological systems in high throughput settings, extract high-quality DNA in less than two an hours with minimal sample input and without the use of harmful chemicals  or mechanical homogenization, and extract DNA from diverse sample types, including blood, and cell and tissue samples, in each case when using the HT Nanobind DNA Extraction kits; and other future events. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this press release and are based on current expectations, and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements, including, challenges inherent in developing, manufacturing, launching, marketing and selling new products; potential product performance and quality issues; rapidly changing technologies and extensive competition in genomic sequencing; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Readers are strongly encouraged to read the full cautionary statements contained in PacBio's filings with the Securities and Exchange Commission, including the risks set forth in PacBio's Forms 8-K, 10-K, and 10-Q. PacBio disclaims any obligation to update or revise any forward-looking statements. Readers are strongly encouraged to read the full cautionary statements contained in PacBio's filings with the Securities and Exchange Commission, including the risks set forth in PacBio's Forms 8-K, 10-K, and 10-Q. PacBio disclaims any obligation to update or revise any forward-looking statements.

Contacts
Investors:
Todd Friedman
This email address is being protected from spambots. You need JavaScript enabled to view it.            

Media:
Lizelda Lopez
This email address is being protected from spambots. You need JavaScript enabled to view it.